Most Read

The company sought approval for the combination therapy to treat previously untreated mantle cell lymphoma (MCL) adult patients not suitable for autologous stem cell transplantation (ASCT). Jointly developed

The company intends to utilise the funds to continue its ongoing Phase Ib clinical trial and begin two additional Phase Ib studies this year. It also plans to

A drug-free nasal spray, Bentrio is designed for personal protection against airborne viruses and allergens. It forms a protective gel layer on the nasal mucosa upon application into

As per the terms of the updated and restated deal, Helsinn will obtain an exclusive license for infigratinib commercialisation in the US. The company will also develop, produce,

The funding round included new investors Schroders Capital, 3B Future Health Fund, Caribou Property, and British Patient Capital. Existing investors Epidarex Capital and ALSA Ventures have also participated

Co-led by Canaan Partners and Red Tree Venture Capital, the financing round included significant investment from Johnson & Johnson Innovation – JJDC. SV Health Investors and Novo Holdings

Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that is indicated to treat anaemia of CKD in adult patients not on dialysis and on dialysis.

The regulatory agency issued a complete response letter (CRL) to the company’s New Drug Application (NDA) for lenacapavir mentioning Chemistry Manufacturing and Controls (CMC) issues related to its

Jointly developed and commercialised by Pharmacyclics, Imbruvica (ibrutinib) is a once-daily oral medication that blocks the Bruton’s tyrosine kinase (BTK) protein. The sNDA seeks approval for the drug